FDA Grants Rare Pediatric Disease Designation to PAS-004, Opening Door to Potential $150M+ Priority Review Voucher
Summary
Pasithea Therapeutics announced that the FDA has granted Rare Pediatric Disease Designation (RPDD) to its drug candidate, PAS-004, for the treatment of Neurofibromatosis Type 1 (NF1). This designation is highly significant as it makes the company eligible to receive a Priority Review Voucher (PRV) upon eventual New Drug Application (NDA) approval. Historically, PRVs have sold for $150-$205 million, representing a potential value many times the company's current market capitalization. This substantially de-risks the development pathway and provides a significant potential non-dilutive funding source. Investors will now closely watch the progress of PAS-004 through its ongoing Phase 1/1b clinical trials, as this designation is a major positive catalyst for the micro-cap biotech.
At the time of this announcement, KTTA was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.5M. The 52-week trading range was $0.28 to $3.79. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.